sector medic suppli devic
pave way improv momentum
messag despit plenti put take thought updat
posit overal j-code decis disappoint progress sinuva
coverag encourag new balloon sinuplasti program add anoth
potenti futur growth driver mix j-code longer overhang
street expect reset believ achiev level see
stock well-posit rebuild momentum head lower pt
slightli reflect revis estim reiter buy rate
sinuva get j-code overal reimburs pictur
improv intersect secur coverag five six major nation payer ci
lone holdout repres live manag note prior author
approv rate quarter privat insur recommend use unassign code
case result lack dedic j-code like make difficult
medicar patient receiv sinuva near-term expect major
hindranc non-medicar popul intersect intend reappli dedic code
next year time believ elimin exist code
map sinuva cycl could spur agenc come differ conclus
said felt time j-code decis
assign import street warrant given potenti impact
remain bigger concern view gener lack comfort within
ent commun buy-and-bil pathway procur sinuva front
intersect continu accru databas eob demonstr payment level
differ insur across differ region total sinuva custom
overal purchas product way today end
intersect report vast major claim submit thu far paid
averag payment rate line expect cover cost product plu
reason mark-up importantli despit case databas point
manag believ alreadi posit make strong case physician
may fenc encourag view worri
much larger number case could requir make cogent argument
foundat final place come execut six
month sinuva launch littl gone way manag predict
start year howev broad payer coverag larg instal base
train physician ampl resourc avail aid reimburs claim
submiss believ piec place sinuva begin demonstr
meaning traction less clear us time initi slope ramp
intersect intend shift train new doc attempt drive increas
util exist account lower forecast sinuva sale
better reflect uncertainti model call revenu vs
previous howev confid long-term growth potenti product remain
unchang see sinuva revenu ramp combin
low-double-digit growth base propel/contour busi drive annual sale
growth model
addit new drug-coat sinuplasti balloon could enhanc
intersect long-term growth potenti call manag disclos
prepar kick new clinic trial ascend evalu perform
intern develop balloon sinuplasti system coat mometason furoat
studi expect random patient treatment either intersect balloon
commerci avail balloon test whether addit drug improv
page analyst certif import disclosur
estim balloon sinu dilat market today market
leader acclar busi unit roughli share follow
entellu franchis snn also small presenc space
balloon use grown rapidli recent year particularli offic favor
reimburs made favorit tool ent look shift less complex procedur
hospit set approv intersect expect drug-coat balloon
reimburs code think ad balloon portfolio
make strateg sens intersect way leverag sale forc increas
presenc offic key question view whether addit drug element
materi improv outcom popul importantli compani alreadi
complet small pharmacokinet studi demonstr proprietari design
achiev suffici drug deposit index procedur maintain therapeut effect
heal phase manag wile share detail data
call howev also remain seen whether ascend suffici support
fda approv product whether anoth studi could requir assum trial
enough estim intersect could receiv approv late earli
howev point assum contribut balloon model
favor risk/reward head reiter buy model call
intersect post net loss per share total revenu
compar prior forecast net loss per share
sale project revenu growth
compani net loss narrow per share long-term continu see
potenti intersect return growth profil sinuva launch ramp
share trade today multipl commensur growth
compani see risk/reward stock favor lower price target
take account revis estim signific upsid potenti
target current level reiter buy rate
page analyst certif import disclosur
intersect develop drug/devic combin product treatment chronic sinus
compani propel implant dramat improv outcom fess patient
reduc complic need revis procedur market opportun
 alon intersect achiev solid traction propel sinc launch
introduct contour version product design specif
peripher sinus help drive penetr fess
procedur see ampl runway propel/contour go forward
expect investor focu shift intersect pipelin particular sinuva implant
patient recurr symptom follow sinu surgeri see sinuva
increment opportun potenti provid difficult patient popul
minimally-invas altern revis surgeri someth check indic
repres signific unmet clinic need driven continu penetr base
product portfolio earli adopt sinuva estim intersect grow
revenu compound-annual-growth-rate next four year combin gross margin
strong balanc sheet path profit believ outlook stack
well best growth stori med-tech
valu intersect ent primarili ev/sal basi use repres group
small-cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade ntm
sale signific premium intersect multipl lower
price target base multipl unchang revis
forward ntm sale estim signific upsid potenti target current
level assign share buy rate
downsid risk rate price target includ commerci payer reduc
reimburs fess procedur propel adopt fall short street
expect sinuva launch fall short street expect
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
